VIKTORIA-1 May Sharpen Post-CDK4/6 Choices in PIK3CA-Mutant HR+ Breast Cancer

VIKTORIA-1 is emerging as one of the more closely watched metastatic breast cancer readouts at ASCO because it addresses a familiar and difficult clinical problem: what to offer patients with HR-positive/HER2-negative, PIK3CA-mutant advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor.

At ASCO 2026, investigators presented data from the PIK3CA-mutant cohort evaluating gedatolisib, an investigational pan-PI3K/mTOR inhibitor, in combination with fulvestrant with or without palbociclib. The study compared those approaches with alpelisib plus fulvestrant, an established PI3K-targeted option in this molecularly defined setting. Eligible patients had HR-positive/HER2-negative advanced breast cancer with prior CDK4/6 inhibitor plus aromatase inhibitor therapy, no prior chemotherapy for advanced disease, no prior PAM pathway inhibitor, measurable disease, and HbA1c below 6.5%.

The reported results showed that both gedatolisib-based regimens significantly improved progression-free survival compared with alpelisib plus fulvestrant in the PIK3CA-mutant cohort. Median progression-free survival was 11.1 months with gedatolisib plus fulvestrant and palbociclib compared with 5.6 months with alpelisib plus fulvestrant, corresponding to a hazard ratio of 0.50; 95% CI, 0.37-0.68; P<0.0001. The gedatolisib doublet arm showed a median progression-free survival of 11.3 months compared with 5.6 months with alpelisib plus fulvestrant, corresponding to a hazard ratio of 0.51; 95% CI, 0.33-0.79; P<0.0013, an important finding because it addresses whether all patients need continued CDK4/6 inhibition in this setting.

The full data are likely to shape discussion around the post-CDK4/6 treatment sequence, particularly for patients whose tumors remain appropriate for endocrine-based therapy but require a more active targeted partner.

A Broader Attack On The PAM Pathway

VIKTORIA-1 was designed around a biological question that has been difficult to answer in practice: whether broader inhibition of the PI3K/AKT/mTOR, or PAM, pathway can improve outcomes compared with targeting one component of the pathway.

Gedatolisib is designed to inhibit all four class I PI3K isoforms and mTORC1/2. That distinguishes it from therapies directed primarily at PI3K-alpha and raises the possibility that broader pathway blockade may help delay or overcome resistance mechanisms that emerge after endocrine therapy and CDK4/6 inhibition.

Dr. Rachel Layman, professor of breast medical oncology at MD Anderson Cancer Center and a co-author of VIKTORIA-1, said the rationale for gedatolisib is rooted in shutting down more of the pathway at once.

“What is different about this drug is that it is inhibiting both mTOR and PI3K,” Dr. Layman said, adding that preclinical work also suggested AKT suppression. “So essentially the entire PAM pathway is being shut down with the molecule, and that really in theory would help reduce the risk of developing resistance.”

That principle is central to how the trial may be interpreted. The question is not only whether gedatolisib improves progression-free survival. It is whether broader pathway inhibition can offer a clinically useful balance of disease control and tolerability in a population that already has several competing post-CDK4/6 options.

The Triplet And Doublet Answer Different Clinical Questions

The trial’s three-arm design is one of its most clinically useful features. The gedatolisib triplet tests whether continued CDK4/6 inhibition with palbociclib adds value when combined with fulvestrant and PAM pathway inhibition after prior CDK4/6 exposure. The gedatolisib doublet asks whether some patients may be treated effectively without adding another CDK4/6 inhibitor.

In the ASCO presentation, the triplet produced a median progression-free survival of 11.1 months versus 5.6 months with alpelisib plus fulvestrant. The doublet produced a median progression-free survival of 11.3 months versus 5.6 months with alpelisib plus fulvestrant. The doublet comparison should be described carefully because it was a secondary endpoint and the gedatolisib doublet arm was smaller, with 52 patients, compared with 155 patients each in the triplet and alpelisib/fulvestrant arms.

Dr. Layman said the doublet arm addresses a practical issue for oncologists: whether all patients need the added cost, toxicity, and complexity of another CDK4/6 inhibitor.

“There’s also the question: do you actually need the CDK4/6 inhibitor?” she said. “It’s another drug that adds cost, that adds toxicity, that adds complexity for patients.”

If the doublet data remain clinically persuasive after full review, the study may give physicians more flexibility. A triplet approach may be more appropriate for patients who can tolerate more intensive endocrine-based therapy and need maximal disease control, while a doublet could be attractive for patients with prior CDK4/6-related toxicity, comorbidities, treatment fatigue, or a strong preference to avoid additional oral therapy.

Dr. Layman framed that flexibility as part of the appeal of the study.

“I think it’s really nice to have this data,” she said, “and it does give physicians and patients a choice whether they would want to do a triplet therapy or a doublet therapy based on patient preference, patients’ other medical problems and side effects that they may have had in the past.”

Toxicity May Determine How The Regimen Is Used

The efficacy signal is only one part of the VIKTORIA-1 story. In routine practice, PI3K pathway inhibition is often limited by adverse effects, especially hyperglycemia, rash, diarrhea, and treatment discontinuation. That makes the safety profile of gedatolisib particularly important.

In the ASCO data, the abstract did not report overall grade 3 or higher adverse event rates, but rates of discontinuation of assigned therapy due to treatment-related adverse events were low: 2.6% with the gedatolisib triplet, 3.8% with the gedatolisib doublet, and 7.1% with alpelisib plus fulvestrant. Grade 3 or higher hyperglycemia occurred in 2.6% of patients receiving gedatolisib plus fulvestrant and palbociclib, 0% receiving gedatolisib plus fulvestrant, and 13.8% receiving alpelisib plus fulvestrant. Rates of treatment-related stomatitis were 61.4%, 61.5%, and 34.2% for the gedatolisib triplet, gedatolisib doublet, and alpelisib/fulvestrant arms, respectively; grade 3 stomatitis occurred in 16.3%, 5.8%, and 5.3%, respectively. 

Dr. Layman said tolerability, particularly hyperglycemia, may be one of the most clinically meaningful aspects of the gedatolisib experience.

“One major problem with these drugs is that, by their very nature of inhibiting this pathway, you get a lot of side effects,” she said. “The pathway is important in normal cells as well, not just cancer cells.”

She added that with gedatolisib, “we’re not seeing as much toxicity, in particular the hyperglycemia,” and noted that the drug had been tolerated in some patients with diabetes who were not receiving insulin.

That point could matter in practice because patients with diabetes or substantial metabolic risk may not be ideal candidates for some existing PAM pathway inhibitors. If the final safety data confirm a lower rate of clinically significant hyperglycemia, gedatolisib could become relevant for patients who previously had limited ability to receive PI3K pathway-directed therapy.

The IV Schedule Is A Real-World Consideration

Gedatolisib’s intravenous administration may also influence uptake. Many patients with HR-positive metastatic breast cancer have become accustomed to oral targeted therapies, and an IV regimen can add infusion-center time, transportation barriers, and scheduling complexity.

Dr. Layman acknowledged that concern but said the route of administration should be weighed against efficacy and tolerability.

“Patients mostly want a very effective treatment and also an effective treatment that has fewer side effects,” she said. “If the patient feels better on this medication, even if it’s IV, I think patients will still want to do it.”

That tradeoff is likely to be part of clinical decision-making if gedatolisib moves toward regulatory approval. For some patients, an IV schedule may be a disadvantage. For others, particularly those who have struggled with oral targeted therapy toxicity or adherence, the tradeoff may be acceptable if the efficacy and safety profile are compelling.

What The Data Mean Now

With the full ASCO presentation now available, the clinical interpretation of VIKTORIA-1 rests on three linked issues: the magnitude of the progression-free survival benefit, the safety and discontinuation profile, and the practical value of having both triplet and doublet gedatolisib-based options.

Dr. Layman said she believes the data could be practice-changing, particularly because they may expand targeted-treatment options for patients who are not ideal candidates for existing PAM pathway inhibitors.

“There are patients that may be eligible to take [gedatolisib] who aren’t eligible to take some of the other PAM pathway inhibitors because of diabetes,” she said. “The fact that this shows less toxicity with hyperglycemia suggests that this will open up options for patients where they really didn’t have an option to target this pathway in the past.”

That interpretation will need to be considered alongside regulatory status, access, infusion logistics, and how clinicians prioritize competing targeted therapies after CDK4/6 progression.

A Potential New Option, Pending Regulatory Review

Gedatolisib is not yet approved in this setting, so VIKTORIA-1 should not be framed as an immediate standard-of-care replacement. But the trial adds important evidence to the evolving post-CDK4/6 treatment discussion in HR-positive/HER2-negative metastatic breast cancer.

If the final data are viewed as clinically meaningful by regulators and guideline committees, gedatolisib-based therapy could become a relevant option for patients with PIK3CA-mutant disease, particularly those who remain candidates for endocrine-based treatment and need a targeted approach with a potentially different toxicity profile from existing PI3K pathway inhibitors.

For oncologists, the practical question after ASCO is how to match the regimen to the right patient: triplet versus doublet, IV versus oral treatment burden, metabolic risk versus pathway inhibition, and targeted therapy versus other post-CDK4/6 strategies.

VIKTORIA-1 does not simplify the sequencing question entirely. But it may add a new and biologically distinct option to a setting where physicians are increasingly making treatment decisions based on tumor genomics, prior therapy, toxicity, and patient goals.